Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy

NCT01202903 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

616

Enrollment

INDUSTRY

Sponsor class

Conditions

Persistent Allergic Asthma

Interventions

DRUG: Omalizumab
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals

Collaborators

[object Object]